Biopharma companies are sitting on roughly $1.2 trillion in firepower, according to a recent report by Ernst & Young. But firepower to spend on deals — which includes cash, existing debt, and market capitalization — won’t necessarily translate into multibillion-dollar transactions, at least in the short term.
Real-world data (RWD) and real-world evidence (RWE) can be relevant and essential to bringing innovation to patients and gaining regulatory approval. This article describes the sources of real-world data, how to use real-world data to enhance a development program, and how RWD and RWE advance regulatory decision-making.
Tufts CSDD is conducting an important new survey to assess how pharma and biotech companies are incorporating patient engagement into their drug development organizations and operations. Take the survey here.
Every initiative to improve healthcare requires high-quality data. Whether an organization is seeking improved outcomes, higher quality, or lower costs, learn why it should start with in-depth, reliable, and representative data.